Abstract

e12033 Background: Statistics of Multiple Primary Cancers (MPC) are dominated by Breast Cancer. A study of MPC involving non-breast sites might highlight subsets with special features. Methods: Between 1 January 1999 and 31 December 2009 we encountered 177 patients with MPC among a total of 5481 cases. Out of these 97 cases involving non-breast sites only were studied. Analysis was done with respect to sex, synchronous (sync) versus metachronous (meta), age groups- I: 20 to 39 yrs; II: 40-59 yrs; III: 60 yrs and above; Combinations: solid- solid neoplasms (SS), solid- hematologic neoplasms (SH), hematologic - hematologic neoplasms (HH). Results: Males: 58 (59.79%) female: 39 ( 40.21%) synchronous 28 (28.37%) metachronous 69 (71.13%) , age groups I 08 (8.25%) II 28 (28.86%) III 61 (62.89%) combinations of neoplasms SS: 69 (71.14%) SH 24 (24.74%) HH: 04 (4.12%). Top 5 Subsets: 72 (74.23%) SS/meta/male 25 (25.77% ) SS/meta/female 22 (22.68%) SS/sync/male 10 (10.31%) SH/meta/male 09 (9.28%) SH/sync/male 06 (6.19%) Other subsets < 3 (3.09%) each. Conclusions: Our Cohort of MPC involving non-breast sites showed preponderance of male sex, metachronous neoplasms, age group III, SS neoplasms. Top 5 common solid neoplasms were: gastrointestinal, urologic, lung, gynecologic and head and neck cancer (HNSCC). Top 2 hematologic neoplasms: CLL and multiple myeloma. Metachronous SS Neoplasms were increased in II and III age groups in both sexes. Synchronous SS, both synchronous and metachronous SH groups were increased in males, age group III only. Urologic (76.92%), gynecologic (75.00%), HNSCC (75.00%), were Index neoplasms, lung tumors were second primary neoplasms (94.74%).Gastrointestinal tumors were equally distributed (Index tumors 51.72%). Multiple myeloma was associated with synchronous MPC and CLL with metachronous MPC. No significant financial relationships to disclose.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call